[go: up one dir, main page]

AR013498A1 - Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa - Google Patents

Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa

Info

Publication number
AR013498A1
AR013498A1 ARP980104605A ARP980104605A AR013498A1 AR 013498 A1 AR013498 A1 AR 013498A1 AR P980104605 A ARP980104605 A AR P980104605A AR P980104605 A ARP980104605 A AR P980104605A AR 013498 A1 AR013498 A1 AR 013498A1
Authority
AR
Argentina
Prior art keywords
alpha
ifn
amantadine
chronic hepatitis
treatment
Prior art date
Application number
ARP980104605A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR013498A1 publication Critical patent/AR013498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion provee el uso de IFN-alfa en asociacion con amantadine para la manufactura de medicamentos para el tratamiento deinfecciones cronicas de hepatitis C. La presente invencion provee también medicamentos que contienen IFN-alfa y amantadine como una preparacioncombinada para uso simultáneo, separado o secuencial en terapia de infecciones cronicas de hepatitis C. La presente invencion provee además un método paratratar infecciones cronicas de hepatitis C en pacientes que necesitan dicho tratamiento que comprende administrar una cantidad de IFN-alfa en asociacioncon una cantidad de amantadine que es eficaz para tratar la hepatitis C.
ARP980104605A 1997-09-18 1998-09-16 Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa AR013498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97116220 1997-09-18

Publications (1)

Publication Number Publication Date
AR013498A1 true AR013498A1 (es) 2000-12-27

Family

ID=8227366

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104605A AR013498A1 (es) 1997-09-18 1998-09-16 Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa

Country Status (12)

Country Link
US (1) US20030031647A1 (es)
EP (1) EP1011714A2 (es)
JP (1) JP2001516725A (es)
KR (1) KR100364938B1 (es)
CN (1) CN1276730A (es)
AR (1) AR013498A1 (es)
AU (1) AU746648B2 (es)
BR (1) BR9812466A (es)
CA (1) CA2302834A1 (es)
TR (1) TR200000728T2 (es)
WO (1) WO1999013894A2 (es)
ZA (1) ZA988519B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279819A1 (en) * 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
EP2044150B1 (en) * 2006-07-21 2014-01-15 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1998019670A2 (en) * 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C

Also Published As

Publication number Publication date
JP2001516725A (ja) 2001-10-02
AU746648B2 (en) 2002-05-02
CN1276730A (zh) 2000-12-13
TR200000728T2 (tr) 2000-09-21
KR20010024044A (ko) 2001-03-26
CA2302834A1 (en) 1999-03-25
EP1011714A2 (en) 2000-06-28
KR100364938B1 (ko) 2002-12-18
WO1999013894A3 (en) 1999-06-03
US20030031647A1 (en) 2003-02-13
ZA988519B (en) 1999-03-18
BR9812466A (pt) 2000-09-19
AU9743098A (en) 1999-04-05
WO1999013894A2 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
ES2162393T3 (es) Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
DK0776202T3 (da) Liposomalt indkapslet taxol, dets fremstilling af dets anvendelse
NO20032027D0 (no) Effektive antitumorbehandlinger
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
UY24063A1 (es) Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
ES2103811T3 (es) Terapia antiviral.
BR9708037A (pt) Método para o tratamento de abuso de substância
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
DK1150981T3 (da) Terapeutisk necleosidforbindelse
WO2004064855A8 (de) Medikament und verwendung zur tumortherapie
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica
UA49320A (uk) Спосіб лікування пневмоцистозу у хворих на хронічний бронхіт
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту

Legal Events

Date Code Title Description
FA Abandonment or withdrawal